Epigenomics said last week that its partner Abbott has launched an in vitro diagnostic test for colorectal cancer in Europe and the Asia/Pacific market.
The test is based on Epigenomics' Septin9 biomarker. Abbott holds non-exclusive worldwide rights to the biomarker under a licensing agreement signed in late 2007. It is optimized for Abbott's RealTime system m2000, an automated PCR platform.
Abbott is marketing the test as the Abbott RealTime mS9 Colorectal Cancer Assay.
Epigenomics said that the launch of the test triggers a milestone payment, and that it is also entitled to royalties on product sales as well as certain sales-related milestones.